Literature DB >> 8980354

Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas.

A Matsuno1, T Nagashima, R Matsuura, H Tanaka, M Hirakawa, M Murakami, A Tamura, T Kirino.   

Abstract

Wild type p53 protein has been shown by recent investigations to be involved in the negative regulation of cell proliferation, whereas aberrant p53 protein has lost this negative regulation of cell growth. Wild type p53 protein, which has a very short half-life, has generally been considered to be undetectable using immunohistochemical methods; however, according to a recent report, wild type p53 protein may accumulate in the nuclei because of a defective ubiquitin pathway. Aberrant p53 protein has a longer half-life, and thus is visible using immunohistochemical methods. In this study, both the proliferative potential represented by the MIB-1 staining index (SI) and the immunoreactivity of p53 protein in 51 intracranial meningiomas were studied applying immunohistochemical staining methods to archival paraffin sections. The correlation among MIB-1 SI, p53 immunoreactivity, histopathologic findings and the clinical course of the meningiomas was also analyzed retrospectively. Although it is not possible with available reagents to distinguish between aberrant p53 protein and wild type p53 protein, statistical analyses show that p53 protein was immunostained both in meningiomas with high MIB-1 SI and in recurrent meningiomas. This demonstrates the close relationship among p53 immunoreactivity, MIB-1 SI, and recurrence; therefore, the presence of p53 protein by immunohistochemical examination may suggest the proliferative activity of meningioma and is capable of serving as a predictor of future recurrence.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980354     DOI: 10.1093/ajcp/106.6.776

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Prognostic significance of p53 and p21WAF1/CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas.

Authors:  Y Kamei; M Watanabe; T Nakayama; K Kanamaru; S Waga; T Shiraishi
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

2.  Proliferation potential of spinal meningiomas.

Authors:  Florian Roser; Makoto Nakamura; Mattia Bellinzona; Rainer Ritz; Helmut Ostertag; Marcos S Tatagiba
Journal:  Eur Spine J       Date:  2005-05-31       Impact factor: 3.134

3.  Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo.

Authors:  Reshu Gupta; Venkateswara Rao Gogineni; Arun Kumar Nalla; Chandramu Chetty; Jeffrey D Klopfenstein; Andrew J Tsung; Sanjeeva Mohanam; Jasti S Rao
Journal:  Int J Oncol       Date:  2011-02-02       Impact factor: 5.650

4.  Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression.

Authors:  Nives Pećina-Šlaus; Anja Kafka; Tomislav Vladušić; Davor Tomas; Monika Logara; Josip Skoko; Reno Hrašćan
Journal:  Int J Exp Pathol       Date:  2016-06-12       Impact factor: 1.925

5.  Abundant immunohistochemical expression of dopamine D2 receptor and p53 protein in meningiomas: follow-up, relation to gender, age, tumor grade, and recurrence.

Authors:  G Trott; J F S Pereira-Lima; C G S Leães; N P Ferreira; L M Barbosa-Coutinho; M C Oliveira
Journal:  Braz J Med Biol Res       Date:  2015-03-03       Impact factor: 2.590

6.  Clinical features and treatment outcome of chordoid meningiomas in a single institute.

Authors:  Tae Keun Jee; Kyung-Il Jo; Ho Jun Seol; Doo-Sik Kong; Jung-Il Lee; Hyung Jin Shin
Journal:  J Korean Neurosurg Soc       Date:  2014-09-30

7.  Nucleotide variations of TP53 exon 4 found in intracranial meningioma and in silico prediction of their significance.

Authors:  Anja Bukovac; Anja Kafka; Reno Hrašćan; Tomislav Vladušić; Nives Pećina-Šlaus
Journal:  Mol Clin Oncol       Date:  2019-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.